
Researchers at the Salk Institute have introduced a groundbreaking genomic sequencing method called Superb-seq that significantly improves the safety and precision of CRISPR gene-editing therapies. Published in the journal Nature Methods, the technique enables scientists to simultaneously detect both intended target edits and unintended off-target mutations across individual cells while measuring how those alterations affect gene activity. By providing a complete molecular readout at single-cell resolution, Superb-seq removes one of the biggest hurdles in clinical biotechnology, allowing medical researchers to verify genetic therapies before they reach patients.